11.21.22 -- Partners Ready To Support Your Post-Approval Studies

Cmed is a trusted data expert for large scale and complex projects. With 140 strategically located data and analytics staff, 20 years' of experience and hundreds of trials managed to date, we deliver flexible partnering solutions. Our data and analytics expertise with flexible technology helps you bridge the knowledge gap between clinical trials and clinical practice.

inSeption provides medical writing services as well as strategic submission planning expertise to ensure that your application is of the highest quality. Our highly experienced, fully dedicated team integrates with your organization to credibly manage the complexities of timeline creation and management, resourcing, document interdependencies, and transmission through the Electronic Submission Gateway (ESG).

OCT Oncology is your go-to solution from a leading Eastern European CRO to ensure timely enrollment and study success.

Bioforum offers premium medical writing services across all therapeutic areas and fields within biomedical sciences. All of our writing experts hold doctorates, and have many years of writing experience.

A small biotech sponsor developing a new treatment for carcinoma asked for assistance with their trial design. Working with a constrained R&D budget, the challenge was to gather the evidence in a cost-effective manner and use a stage-gate approach for the funding. Explore the solutions uncovered in this case study.

Support your local safety needs and drive consistency with global requirements through end-to-end solutions with regulatory-focused medical experts and leading technologies.

Medidata AI Commercial Data Solutions (CDS) has the advanced analytics experience and leading-edge technology to provide the rapid insights needed to keep your business moving forward.

Our team excels at understanding the ever-changing and complex healthcare market and helping clients solve issues. Learn about the payer challenges, potential reimbursements, and the competition to consider.  

Researching rare disease requires comfort with the unknown, something we’ve developed over years of studying some of the rarest conditions. Our work spans all aspects of clinical trials and drug development, encompassing more than 190 rare disease studies across multiple indications in the past five years with 7 successful drug approvals and 3 breakthrough designations.

We support successful post-marketing pharmacovigilance (PV) expertise for pharmaceutical drugs, biologics, natural health products and medical devices. Our trustful foundation creates longstanding client relationships.

This webinar will explore the RWE/RWD landscape and focus on those situations in which a prospective observational study or registry presents a more optimal solution.